A Phase 1, Multicenter, Open-Label Study of BMS-986553, CD19 In Vivo Chimeric Antigen Receptor (CAR) T Cells, in Participants With Refractory Autoimmune Diseases

Bristol-Myers Squibb

Summary

The purpose of this study is to evaluate the safety and tolerability of BMS-986553, CD19 in vivo Chimeric Antigen Receptor (CAR) T cells, in participants with refractory autoimmune diseases including systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), systemic sclerosis (SSc), rheumatoid arthritis (RA), and Sjögren's disease (SjD).

Eligibility

Age range: 18+ years
Sex: All
Healthy volunteers: No

Detailed criteria

Inclusion Criteria: * SLE participants: Must have diagnosis of SLE defined as fulfilling the 2019 ACR/EULAR classification criteria of SLE. * IIM participants: Must have diagnosis of IIM defined as fulfilling the 2017 ACR/EULAR classification criteria for probable or definite IIM. * SSc participants: Must have diagnosis of SSc defined as fulfilling 2013 ACR/EULAR classification criteria for SSc. * RA participants: Must have diagnosis of RA, defined as fulfilling 2010 ACR/EULAR criteria for RA. * Primary SjD Participants: Must have diagnosis fulfilling the 2016 ACR/EULAR Classification Criteri…

Locations (23)

Local Institution - 0064
Newport Beach, California
Local Institution - 0001
Worcester, Massachusetts
Local Institution - 0004
Ann Arbor, Michigan
Local Institution - 0013
Saint Paul, Minnesota
Local Institution - 0062
Omaha, Nebraska
Local Institution - 0007
Morristown, New Jersey

Summary

Eligibility

Interventions

Locations (23)